Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chinese Patent Office
Teva
Colorcon
AstraZeneca
US Department of Justice
Julphar
Deloitte
Fish and Richardson

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,932,610

« Back to Dashboard

Which drugs does patent 8,932,610 protect, and when does it expire?

Patent 8,932,610 protects OTOVEL and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 8,932,610
Title:Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Abstract: A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.
Inventor(s): Ruiz I Pol; Jaume (Esplugues de Llobregat, ES), Izquierdo Torres; Francisca (Esplugues de Llobregat, ES)
Assignee: Laboratorios Salvat, S.A. (Esplugues de Llobregat (Barcelona), ES)
Application Number:12/730,681
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Dosage form;

Drugs Protected by US Patent 8,932,610

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Laboratorios Salvat OTOVEL ciprofloxacin hydrochloride; fluocinolone acetonide SOLUTION/DROPS;OTIC 208251-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ACUTE OTITIS MEDIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,932,610

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10155005Mar 1, 2010

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cipla
Covington
Medtronic
McKinsey
Express Scripts
Chinese Patent Office
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.